glutathione metabolism and its role in hepatotoxicity The multifaceted of ferroptosis liver disease The biochemistry of acetaminophen hepatotoxicity

The transcript and metabolite networks affected by the two clades of Arabidopsis glucosinolate biosynthesis regulators

We expect DDIs between PrO(D) and clopidogrel, prasugrel, and ticagrelor, as CYP3A4 and CYP2C19 are involved in the bio-activation of clopidogrel and prasugrel and metabolism of ticagrelor [52,53,54,55,56]

doi: 10.1016/j.ymgme.2014.09.003 44 HartPABradleyDConwellDLDunganKKrishnaSGWyneKet al

Wnt/-catenin signaling: components, mechanisms, and diseases

Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population